Last reviewed · How we verify

Usual treatment for ADHD

Puerta de Hierro University Hospital · Phase 3 active Small molecule

Stimulates the brain to increase focus and attention by increasing the levels of certain neurotransmitters.

Stimulates the brain to increase focus and attention by increasing the levels of certain neurotransmitters. Used for Attention deficit hyperactivity disorder (ADHD).

At a glance

Generic nameUsual treatment for ADHD
SponsorPuerta de Hierro University Hospital
Drug classCentral nervous system stimulant
TargetDopamine transporter
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

This is achieved by increasing the levels of dopamine and norepinephrine in the brain, which helps to improve attention and reduce impulsivity. This is done by blocking the reuptake of these neurotransmitters, allowing them to stay in the synaptic cleft for longer periods of time.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: